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the change in height SDS in the first year.  Conclusion: High-
er insulin sensitivity at the start of GH therapy is associated 
with greater first-year growth response to GH, and could be 
a promising parameter in selecting prepubertal short SGA 
children for GH treatment. However, this finding needs to be 
confirmed in larger studies.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 During the first 2 years of life, the majority of children 
born small for gestational age (SGA) present catch-up 
growth in weight and length  [1, 2] . Increased insulin se-
cretion has been linked to patterns of this rapid postnatal 
catch-up in length of SGA infants  [3] . On the other hand, 
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 Abstract 
 Aim: To study the relationship between insulin sensitivity 
and growth response in short children born small for gesta-
tional age (SGA) treated with growth hormone (GH).  Meth-
ods: Randomized, open-label, 24-month intervention study 
in 40 short prepubertal SGA children [age (mean  8 SD) 5.3 
 8 1.5 years], who either remained untreated (n = 20) or were 
treated with GH (66   g/kg/day; n = 20). Changes in fasting 
glucose, insulin, quantitative insulin sensitivity check index 
(QUICKI), IGF-1 and leptin after 1 and 2 years were studied. 
 Results: Mean height SDS increased from –3.3  8 0.7 to –2.3 
 8 0.7 after 1 year, and to –1.9  8 0.7 after 2 years of treat-
ment. QUICKI decreased significantly (p = 0.008) in the first 
year of GH treatment and stabilized in the second year. Base-
line QUICKI was positively associated (r = 0.40; p  ! 0.05) with 
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reduced insulin sensitivity has been a frequent finding in 
SGA children remaining short after infancy  [4, 5] .
 It is well established that daily administration of re-
combinant growth hormone (GH) promotes a significant 
gain in body height and weight in short SGA children  [6, 
7] . The short-term responses to GH therapy are highly 
variable: in several studies a threefold variation in the 
first-year height SDS increase could be observed  [7, 8] . 
Furthermore, the early changes in stature were found to 
diminish or stabilize in the subsequent years of contin-
ued GH therapy, despite the fact that the circulating IGF-
1 concentrations during GH therapy remain elevated or 
even increase  [9] .
 On the other hand, an impairment of the insulin sen-
sitivity with a two- to threefold increase of both fasting 
and stimulated insulin concentrations during the first 
years of GH treatment have been observed in short pre-
pubertal SGA children  [10, 11] . We hypothesized that a 
greater growth response to GH might be found in those 
SGA children with higher insulin sensitivity at the start. 
Therefore, in this study we analyzed insulin sensitivity 
(from measurements of fasting glucose and insulin) at 
baseline, and after 1 and 2 years of GH therapy. We ad-
ditionally measured fasting leptin and IGF-1 concentra-
tions since both have been related to GH responsiveness 
and catch-up growth in SGA children  [12, 13] .
 Methods 
 Patients 
 Forty children were recruited from the departments of pedi-
atric endocrinology of 8 Belgian hospitals and one Luxembourg-
ian hospital according to the following inclusion criteria: (1) birth 
weight and/or length below –2 SD for gestational age; (2) current 
height below –2.5 SD; (3) height velocity below +1.0 SD (measure-
ments of height at time of inclusion and 12  8 6 months earlier), 
and (4) ages between 3 and 8 years at the start of the study. Exclu-
sion criteria were: (1) prematurity (gestational age below 34 
weeks); (2) endocrine disease including GH deficiency, bone dis-
ease or any severe chronic disease; (3) Turner, Noonan or Down 
syndrome, or other chromosomal abnormalities; (4) current or 
previous irradiation therapy, current or previous (12  8 6 months 
before inclusion) treatment with oral steroids for more than 3 
months, and (5) severe mental retardation. Twenty-two females 
and 18 males were included. The clinical characteristics of the in-
cluded patients are summarized in  table 1 .
 Study Protocol 
 After stratification by the minimization method for gender, 
chronological age, weight SDS and hospital, the children were al-
located to either a GH-treated (n = 20) or untreated group (n = 
20).
 The treated children received recombinant human GH for 2 
years from the start of the study. The dose of GH (Genotonorm, 
Pfizer, USA) was 66   g/kg body weight per day. The dose was 
adjusted to body weight every 6 months. The untreated group was 
followed over 2 years without receiving GH therapy with the op-
portunity to start GH treatment for a period of 2 years after-
wards. The local ethics committees of the participating centers 
approved the study and informed consent was obtained from the 
parents.
 Measurements 
 Assessments of body height, weight and insulin sensitivity 
were performed at baseline and after 1 and 2 years. Measurements 
of standing body height and body weight as well as assessment of 
pubertal development were performed at the local hospital by one 
trained observer. Body height and weight were expressed as SD 
score for chronological age and sex (SDS)  [14] . BMI was calculated 
and expressed as SDS  [14] . Pubertal stages were scored according 
to Tanner  [15, 16] .
 Blood samples were collected in fasting condition at baseline 
and after 1 and 2 years of treatment. Glucose was measured lo-
cally within 2 h after collection and serum was stored for central-
ized analysis of insulin, IGF-1 and leptin. Insulin sensitivity was 
estimated by the quantitative insulin sensitivity check index 
(QUICKI), using the fasting plasma glucose and serum insulin 
concentrations  [17] .
 Changes in height SDS score between start and 1 year and be-
tween 1 and 2 years were calculated for each subject as the mea-
sure of variation in growth response to GH. The first-year change 
in height SDS was chosen as a parameter for the growth-promot-
ing effect of GH and the second-year change as a measure for the 
waning effect of GH therapy.
 Laboratory Assays 
 Plasma glucose concentration was measured by the glucose 
oxidase method on an automated analyzer. Serum insulin was 
measured by a commercial IRMA (Bi-Insulin IRMA 2009, Cis-
Bio International, Gif-sur-Yvette, France). The cross-reactivity 
was  ! 0.0001% with proinsulin and the detection limit was 0.5 
mU/l; the intra- and interassay coefficient of variation were 3.8 
and less than 8%, respectively. Serum IGF-1 was measured by a 
commercial radioimmunoassay (DSL-5600 ACTIVE) and the de-
tection limit was 0.8 ng/ml; the intra- and interassay coefficients 
were 3.7 and 1.5%. Reference data provided by the manufacturer 
were used for the calculation of IGF-1 z-scores. Serum leptin was 
measured with a commercial IRMA (DSL-23100) and the detec-
tion limit was 0.1 ng/ml; the intra- and interassay coefficients 
were 3.9 and 6.7%.
 Statistical Analysis 
 Results are shown as means and SD. First-year changes were 
calculated as the value at 1 year minus the baseline value, and 
second-year changes as the value at 2 years minus the first-year 
value. To adjust for the baseline values, percent changes [(actual 
value – baseline value/baseline value)  ! 100] in QUICKI, IGF-1 
and leptin at 1 and 2 years were calculated. Differences between 
groups were assessed by a mixed between-within ANOVA. Pear-
son’s correlations coefficients were obtained to evaluate the rela-
tionship between quantitative variables. For statistical purposes, 
an extreme baseline QUICKI and IGF-1 and change in QUICKI 
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and IGF-1 values were excluded in the calculation of the regres-
sion coefficients. Percent of variance in changes in QUICKI dur-
ing the first year and second year were calculated as the coeffi-
cient of determination [(square of Pearson’s correlation coeffi-
cient)  ! 100]. Multiple regression and forward step regression 
analysis models for each of the studied hormonal parameters 
were used in the selection of the predictors of the change in 
height SDS.
 Results 
 Baseline Levels and Evolution of Growth Parameters 
 As shown in  table 1 , there were no significant differ-
ences between the two study groups for any of the base-
line growth variables, including growth velocity, which 
was within normal age limits in all subjects. One child in 
the treated group dropped out of the study after 1 year 
because of refusal of further injections. Height velocity 
almost doubled during the first year of GH therapy (5.2 
 8 1.3 vs. 9.8  8 1.4 cm/year), while it did not change in 
the untreated group. In the treated group, height velocity 
decreased significantly during the second year (9.8  8 1.4 
vs. 7.7  8 1.2 cm/year), but remained significantly higher 
compared to the untreated group (7.7  8 1.2 vs. 5.4  8 0.9 
cm/year). Weight gain during the first year averaged 2.9 
 8 0.8 kg in treated children and was twice as high (p  ! 
0.0001) as in the untreated children (1.4  8 0.5 kg). Weight 
gain in the second year was slightly lower than during the 
first year of treatment (2.6  8 0.7 kg), but remained high-
er than in the untreated group.
 The accelerated growth in the GH-treated group in-
duced major changes in height SDS: mean height SDS in-
creased from –3.3  8 0.7 to –2.3  8 0.7 after 1 year and to 
–1.9  8 0.7 after 2 years. A great variability in the growth 
response was observed in the treated patients: the change 
in height SDS ranged between 0.38 and 1.80 in the first 
year and between –0.29 and 0.86 in the second year. BMI 
SDS remained unchanged over the 2-year observation pe-
riod in the treated and untreated group. None of the par-
ticipating children entered puberty during the course of 
the study.
 Baseline Levels and Evolution of Hormonal 
Parameters 
 Annual results of the longitudinal follow-up of fasting 
glucose, insulin, leptin and IGF-1 and the calculated 
QUICKI are shown in  table 2 . At baseline there were no 
differences between the two groups. Serum IGF-1 tripled 
Table 1.  Body height, weight and BMI (SDS) at baseline and follow-up in the GH-treated and untreated groups
Pre-GH 1 year 2 years GLM within subject
p value
GH-treated 
n = 20 (10 males)
Age, years 5.681.6a 6.681.7b 7.581.7c <0.0001
Height, cm 97.089.9a 107.189.5b 114.589.8c <0.0001
Height SDS –3.380.7a –2.380.7b –1.980.7c <0.0001
Weight, kg 13.083.1a 15.883.7b 18.584.3c <0.0001
Weight SDS –3.881.3a –2.881.3b –2.381.2c <0.0001
BMI 13.781.3a 13.881.5b 13.981.3c 0.157
BMI SDS –1.781.1 –1.681.3 –1.581.1e 0.024
Height velocity, cm/year 5.281.3a 9.881.4b 7.781.2c <0.0001
Untreated Age, years 5.181.3a 6.181.3b 7.181.3c <0.0001
n = 20 (8 males) Height, cm 95.187.4a 100.887.2b 106.287.2c <0.0001
Height SDS –3.280.9d –3.180.9 –3.180.9e 0.013
Weight, kg 12.382.5a 13.882.7b 15.482.9c <0.0001
Weight SDS –3.981.4 –3.881.4 –3.781.5e 0.15
BMI 13.581.3a 13.581.4b 13.581.4c 0.978
BMI SDS –2.081.5 –2.081.5 –2.081.5 0.876
Height velocity, cm/year 5.781.2 5.680.8 5.480.9 0.673
a  p < 0.0001 after paired t test between pre-GH and 1 year. b p < 0.0001 after paired t test between 1 year and 2 years. c p < 0.0001 
after paired t test between pre-GH and 2 years. d p < 0.05 after paired t test between pre-GH and 1 year. e p < 0.05 after paired t test 
between pre-GH and 2 years.
GLM = General linear model.
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during the first year of GH therapy (p  ! 0.0001), while a 
smaller increase in the second year of treatment was ob-
served. Serum leptin concentration during GH treatment 
showed a biphasic pattern: a significant (p  ! 0.005) de-
crease in the first year (from 1.5  8 0.9 to 1.1  8 1.13   g/l), 
followed by a significant (p  ! 0.0001) increase in the sec-
ond year (to 4.4  8 2.2   g/l). The fasting insulin concen-
tration almost doubled in the first year (p  ! 0.0001), and 
remained at a similar level in the second year. QUICKI 
decreased significantly (p  ! 0.05) during the first year of 
GH therapy and subsequently stabilized in the second 
year, but remained unchanged in the control group dur-
ing the whole observation period.
 Baseline QUICKI was unrelated to BMI SDS and birth 
weight SDS in the treated group, but correlated negative-
ly with age (r = –0.39; p  ! 0.005), parental adjusted height 
deficit (r = –0.33; p  ! 0.05), leptin concentration (r = 
–0.38; p  ! 0.05), IGF-1 concentration (r = –0.41; p  ! 0.05) 
and change in QUICKI in the first year (r = –0.78; p  ! 
0.0005).
 Associations between Growth Response and Baseline 
Hormonal Parameters 
 As shown in  table 3 , in the GH-treated group baseline 
IGF-1 was negatively associated with the change in height 
SDS in the first year (r = –0.41; p  ! 0.05), whereas pre-
treatment QUICKI was positively associated (r = 0.40;
p  ! 0.05). The correlation between baseline QUICKI and 
the first-year growth response persisted after correction 
for age and IGF-1 (r = 0.36; p = 0.07). Using stepwise mul-
tiple regression analysis including age, baseline IGF-1 
and baseline QUICKI, the first-year change in height SDS 
was best determined by the pretreatment QUICKI: 
change in height SDS = –0.54 + 3.31  ! QUICKI (r = 0.64; 
p  ! 0.005) when outliners were included ( fig. 1 ); and by 
Table 2.  Biological data of both groups at baseline and follow-up
Pre-GH 1 year 2 years GLM within subject
p value
GH treated
n = 20 (10 males)
Glucose, mg/dl 79812 8189 80810f 0.748
Insulin, U/ml 3.081.8a 5.382.1 5.582.9f 0.003
IGF-1, g/l 97891.8a 306.48120.8e 389.48204c <0.0001
IGF-1 SDS –1.680.7a 0.4681.0 0.981.8c <0.0001
Leptin, g/l 1.580.9d 1.181.1b 4.482.2c <0.0001
QUICKI 0.44680.061d 0.39180.046 0.39280.042f 0.033
Untreated
n = 20 (8 males)
Glucose, mg/dl 7689 79812e 7989f 0.344
Insulin, U/ml 2.981.9 3.381.9 3.581.7 0.672
IGF-1, g/l 79.6852.7 97.4856e 167.28108.8c <0.0001
IGF-1 SDS –1.780.6 –1.680.6e –1.181.18f 0.004
Leptin, g/l 2.081.5 2.282.2e 4.983.1f 0.004
QUICKI 0.43980.047 0.42980.055 0.42080.043 0.546
a  p < 0.0001 after paired t test between pre-GH and 1 year. b p < 0.0001 after paired t test between 1 year and 2 years. c p < 0.0001 
after paired t test between pre-GH and 2 years.d p < 0.05 after paired t test between pre-GH and 1 year. e p < 0.05 after paired t test 
between 1 year and 2 years. f p < 0.05 after paired t test between pre-GH and 2 years.
GLM = General linear model.
Table 3.  Correlations between the changes in height SDS and hor-
monal parameters at baseline and their changes during the first 
year of treatment
Delta height SDS 0–1 year
R p value
Age –0.62 0.003
IGF-1 –0.41 0.031
Leptin –0.09 0.710
Insulin –0. 43 0.063
QUICKI 0.40 0.040
Delta IGF-1 0.47 0.040
Delta IGF-1, % 0.68 0.001
Delta leptin 0.06 0.804
Delta leptin, % –0.26 0.30
Delta QUICKI –0.48 0.040
Delta QUICKI, % –0.36 0.137
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age if outliners were excluded: change in height SDS = 
1.29 – 0.70  ! age (years) (r = 0.46; p  ! 0.05). The 1-year 
values of all the studied hormonal parameters were unre-
lated to the change in height SDS in the second year.
 Associations between Growth Response and Changes 
in Hormonal Parameters 
 As shown in  table 3 , the change in height SDS in the 
first year was negatively correlated with the absolute 
change in QUICKI (r = –0.48; p  ! 0.05), also after correc-
tion for age and baseline IGF-1 (r = –0.42; p = 0.07), but 
not with the percent QUICKI increase. On the other 
hand, both the absolute and the percent change in serum 
IGF-1 correlated significantly with the first-year height 
gain. The changes in height SDS during the second year 
correlated positively with the absolute and percent chang-
es in QUICKI observed in the second year (r = 0.60; p  ! 
0.005 and r = 0.53; p  ! 0.05, respectively).
 Discussion 
 Daily administration of high-dose GH in short prepu-
bertal SGA children was found to induce profound catch-
up growth in the first year: a doubling of growth velocity 
and body weight gain in the first year compared to a con-
trol group was observed. The growth response to GH 
therapy, when expressed as change in height SDS, was 
similar to this observed in previous reports using a simi-
lar dose regimen in patient populations with a compa-
rable age range  [6] . Both the child’s age and the adminis-
tered GH dose are the prime variables related to the 
growth response over the first year  [8, 9, 18] . In several, 
but not all studies, the growth response was, as in our 
study, related to the parental adjusted height deficit; how-
ever, in all studies its amplitude and interindividual vari-
ability decreased during the second year  [6, 7, 9] .
 Since clinical predictors have been shown to explain 
only a low percentage of this variability in previous stud-
ies, potential biochemical predictors of the growth re-
sponse have been investigated  [18, 19] . In this study, we 
evaluated in particular whether the amplitude of the 
growth response to GH was associated with pretreatment 
values or changes in fasting insulin, IGF-1 and leptin, 
which have been shown to change significantly during 
GH therapy and have a possible impact on body growth 
 [9, 13, 20–22] . Data on the fasting leptin concentration at 
the start of GH therapy in relation to the first-year growth 
response to GH are conflicting, which might be explained 
either by differences in GH dosing or the pretreatment 
nutritional status of the subjects between studies  [10, 13, 
22] . Serum leptin concentration measured at the start was 
unrelated to the growth response in our subjects, who 
presented with a rather low BMI SDS. In all studies, in-
cluding the present study, the most significant changes in 
leptin concentrations were observed in the first year of 
therapy and were found to be independent of the changes 
in BMI. We found, in accordance with a previous study, 
that the gain in height SDS during the first year on GH 
was negatively related to pretreatment serum IGF-1  [23] . 
Serum IGF-1 concentration has been suggested to be a 
better marker of endogenous somatotropic axis activity, 
which in contrast to stimulated peak GH levels, might 
better predict the first-year growth response to GH in 
SGA children  [9] .
 In our study, QUICKI, known to be a simple and vali-
dated parameter for insulin sensitivity in prepubertal 
children, was also found to be an important predictor for 
the first-year growth response  [24] . Although there is a 
general agreement that the euglycemic hyperinsulinemic 
clamp technique is the best available standard for the 
measurement of insulin action, it is hardly applicable in 
young tiny SGA children and especially in longitudinal 
intervention studies. QUICKI has been shown to be a 
useful screening test for insulin resistance in prepubertal 
children and is probably a better parameter of insulin 
sensitivity than fasting insulin concentration since it bet-
ter reflects the known hyperbolic relationship between 
insulin sensitivity and insulin production, and has better 
repeatability characteristics  [25, 26] .
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 Fig. 1. Scatterplot of QUICKI at the start and change in height SDS 
in the first year of treatment. 
D
ow
nl
oa
de
d 
by
: 
UC
L 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
14
4.
82
.1
08
.1
20
 - 
5/
1/
20
16
 9
:2
4:
33
 A
M
 Insulin Sensitivity and Growth Response Horm Res Paediatr 2012;78:24–30 29
 An important finding of our study was that pretreat-
ment QUICKI as well as the absolute decrease in QUICKI 
during the first year determined the magnitude of the 
height gain during the first year of GH therapy, whereby 
a higher baseline QUICKI and a more severe decrease in 
QUICKI favored a better growth response. This means 
that children with the highest insulin sensitivity at base-
line, who developed a higher degree of insulin resistance 
during treatment, were the best responders to GH treat-
ment. On the other hand, part of the correlations on re-
duction in insulin sensitivity might be explained by the 
phenomenon of regression to the mean.
 Our findings are in contrast with the findings of an 
Australian and a German study, where no correlation be-
tween the degree of fall in insulin sensitivity and the 
growth acceleration during GH therapy was found in 
short SGA children  [10, 11] . The validity of these studies, 
however, can be questioned since prepubertal as well as 
pubertal subjects, who have different degrees of insulin 
sensitivity, were included. Furthermore, in the Austra-
lian study, subjects with very low insulin sensitivity were 
included, and insulin sensitivity was assessed after a vari-
able duration of GH therapy. We observed in a properly 
performed longitudinal study using 12 months of timed 
QUICKI measurements that the insulin sensitivity might 
differ in the same subject, depending on changes in BMI 
SDS and IGF-1 concentrations. We found a mean de-
crease in QUICKI of 10% in the first 12 months, with se-
rum IGF-1 levels explaining 30% of this variance. In fact, 
the elevation of circulating GH levels can mediate the re-
duction in insulin sensitivity. The mechanism of this 
GH-induced reduction in insulin sensitivity involves 
multiple sites in insulin receptor signal transduction  [27] . 
GH may also reduce insulin sensitivity by increasing li-
polysis and circulating free fatty acid levels  [28] .
 Although it is unknown whether the association be-
tween the increase in insulin resistance and the early 
growth response is coincidental or causal in nature, sim-
ilar conditions of accelerated growth, elevated GH secre-
tion and increased insulin resistance are observed during 
infancy in the majority of SGA children with spontane-
ous catch-up growth. A similar condition also occurs 
during puberty in normal children. The compensatory 
hyperinsulinism can be hypothesized as a common un-
derlying factor for this association between accelerated 
growth and increased insulin resistance  [12, 29] . Using 
mouse metatarsal bone growth plated in culture, insulin 
was shown to stimulate metatarsal linear growth and the 
heights of the epiphyseal, proliferative and hypertrophic 
zones in a concentration-dependent fashion  [30] . It re-
mains to be established whether insulin acts in its growth 
stimulation activities via its own receptors, the IGF-1 re-
ceptors or the hybrid IGF-1/insulin receptor  [31] . We ob-
served in our study a negative correlation between the 
changes in growth and insulin sensitivity during the sec-
ond year of treatment. In view of the present observa-
tions, we propose the following hypothesis: while the pre-
vailing insulin sensitivity before GH therapy permits a 
better growth response through the GH-induced com-
pensatory hyperinsulinism initially, this insulin-mediat-
ed growth response can only be maintained during the 
course of GH therapy in those subjects showing some re-
cuperation of the impaired insulin resistance.
 One major practical application emerges from our 
findings: QUICKI could be taken into account to select 
the best candidates for GH therapy. However, future 
studies should be performed to determine whether our 
observations can be confirmed in larger studies since the 
origin of the growth retardation in SGA children is het-
erogeneous and our study population is rather small. 
Furthermore, the observed QUICKI results might be in-
sulin assay-dependent, since insulin measurements de-
pend on the type of assay used (with the newer IRMA 
assays showing a lowering of 20% compared to the RIA 
assays) and the cross-reactivity with proinsulin (in some 
assays, proinsulin accounts for 15–20% of the total 
amount of the fasting insulin)  [32, 33] .
 In summary, we found that insulin sensitivity is an 
important determinant of the growth response to GH 
therapy, is associated with IGF-1 status, and decreases 
significantly during the first year of GH therapy in pre-
pubertal short SGA children. Confirmation of our find-
ings in a larger study is needed in order to determine the 
exact role of QUICKI in the selection of short prepubertal 
SGA children as candidates for high-dose GH therapy.
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